Lovotibeglogene autotemcel
Lovotibeglogene autotemcel (also known as Lenti-D) is a gene therapy product developed by Bluebird Bio for the treatment of cerebral adrenoleukodystrophy (CALD), a rare, genetic neurological disorder. It is an ex vivo gene therapy, which means that it involves modifying the patient's cells outside the body before reinfusing them.
Mechanism of Action[edit]
Lovotibeglogene autotemcel works by introducing a functional copy of the ABCD1 gene into hematopoietic stem cells (HSCs) collected from the patient. The ABCD1 gene is responsible for producing a protein that breaks down certain types of fatty acids. In people with CALD, mutations in the ABCD1 gene lead to the accumulation of very long-chain fatty acids (VLCFAs) in the brain, causing progressive damage to the myelin sheath that protects nerve cells.
The patient's HSCs are collected and then treated with a lentiviral vector carrying a functional copy of the ABCD1 gene. The modified cells are then reinfused into the patient, where they can produce new blood cells that express the functional ABCD1 protein, helping to prevent further accumulation of VLCFAs.
Clinical Trials and Approval[edit]
Lovotibeglogene autotemcel has undergone several clinical trials to evaluate its safety and efficacy. The results of these trials have shown that the therapy can halt the progression of CALD in the majority of patients, with some experiencing improvements in neurological function.
In 2021, the European Medicines Agency (EMA) granted conditional marketing authorization for lovotibeglogene autotemcel, making it the first gene therapy approved for the treatment of CALD.
Side Effects[edit]
As with any medical treatment, lovotibeglogene autotemcel can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, fever, and headache. Serious side effects can include infection, low blood cell counts, and graft-versus-host disease (GVHD).
See Also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
